Navigation Links
Rigel Announces Fourth Quarter and Year End 2010 Financial Results
Date:3/1/2011

SOUTH SAN FRANCISCO, Calif., March 1, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and year ended December 31, 2010.

For the fourth quarter of 2010, Rigel reported a net loss of $17.2 million, or $0.33 per share, compared to a net loss of $25.1 million, or $0.48 per share, in the fourth quarter of 2009. Weighted average shares outstanding for the fourth quarter of 2010 and 2009 were 52.2 million and 51.8 million, respectively.

There was no contract revenue reported in the fourth quarter of 2010. Contract revenue in the fourth quarter of 2009 was $750,000, comprised of a milestone payment from Daiichi Sankyo for the designation of the first lead compound related to the ligase oncology collaboration.

Rigel reported total operating expenses of $19.7 million in the fourth quarter of 2010, compared to $25.9 million in the fourth quarter of 2009. The decrease in operating expenses was primarily due to the completion of the transfer of the fostamatinib open label extension study to AstraZeneca AB (AZ) in September 2010.

In the fourth quarter of 2010, Rigel reported other income of approximately $2.4 million related to the Therapeutic Discovery Tax Credit Program (Section 48D of the Internal Revenue Code).  Rigel received cash proceeds of $2.1 million in the fourth quarter of 2010 and will receive the remaining $0.3 million in 2011.

For the twelve months ended December 31, 2010, Rigel reported contract revenue of $125.0 million and net income of $37.9 million, or $0.73 and $0.72 per basic and diluted share, respectively, compared to contract revenue of $750,000 and a net loss of $111.5 million, or $2.73 per basic and diluted share, for the same period of 2009.  The increase in contract revenue was due mainly to the $100.0 million upfront payment received pursuant to the ex
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
2. Rigels R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study
3. Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders
4. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
5. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
6. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
7. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
8. Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
9. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
10. Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
11. Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... months endedChange %  30 September 201430 September 2013Turnover 546,011 , ... , 384,242 , 339,113 , 13.3 ... , 49.5 Medical Insurance Administration Service Income , ... Devices and Accessories Sales , 94,580 , 142,683 ... 2,917 , 9,219 , (68.4) Impairment Loss on ...
(Date:11/26/2014)... Nov. 26, 2014   Royal Philips ... announced expanded availability of its portfolio of ... wDR, MobileDiagnost Opta[i] , ProGrade and PrimaryDiagnost[ii]. With ... available in the U.S., and availability of all ... offers Philips, customers innovative solutions designed to meet ...
(Date:11/26/2014)... , Nov. 26, 2014 Lexicon Pharmaceuticals, ... the completion of previously announced concurrent financing transactions ... fees and estimated offering expenses, Lexicon anticipates net ...  The transactions consisted of: , a ... pursuant to a registration statement that has been ...
Breaking Medicine Technology:Golden Meditech Announces 2014 / 2015 Interim Results 2Golden Meditech Announces 2014 / 2015 Interim Results 3Golden Meditech Announces 2014 / 2015 Interim Results 4Golden Meditech Announces 2014 / 2015 Interim Results 5Golden Meditech Announces 2014 / 2015 Interim Results 6Golden Meditech Announces 2014 / 2015 Interim Results 7Golden Meditech Announces 2014 / 2015 Interim Results 8Philips expands global reach of diagnostic X-Ray solutions 2Philips expands global reach of diagnostic X-Ray solutions 3Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3
... at High,Risk , ,WASHINGTON, March 9, 2007 ... history of end-stage renal disease (ESRD), and,these individuals appear ... reports a study in the April Journal of,the American ... disease is more frequent in,African-Americans, who are also at ...
... Pharmaceuticals,Inc. (OTCBB:CGXP), a biopharmaceutical company focused on,infectious ... catheter,treated with a Ceragenin compound demonstrated virtually ... In the study, polyurethane catheters treated with ... along with an,untreated catheter. At day 21, ...
Cached Medicine Technology:Nearly 1 in 10 Americans Has A Relative With Kidney Failure 2Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 2Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 3
(Date:11/28/2014)... The Alternative Health Therapies ... five years. The industry has been buoyed by ... either alternative to conventional Western medicine or complementary ... David Whytcross, “industry revenue has been further boosted ... insurance membership.” Meanwhile, improving economic conditions following the ...
(Date:11/28/2014)... 27, 2014 (HealthDay News) -- Planning on seconds at ... heartburn -- clinically known as gastroesophageal reflux disease (GERD) -- ... Jordan Josephson, an ear, nose and throat specialist at Lenox ... to help manage GERD on Thanksgiving: Pace ... least two small meals throughout the day. It,s also a ...
(Date:11/28/2014)... November 28, 2014 An inventor and dental ... on a patient’s filling and it was almost impossible to ... curing light," she said. , The patent-pending Access Light allows ... access to areas of the mouth, as well as avoids ... and safety. Easy to use and clean, it also helps ...
(Date:11/28/2014)... November 28, 2014 A newly released ... an overview of the influenza virus that will soon be ... , The article begins with a brief explanation of ... symptoms. It reminds families that children under the age of ... from chronic diseases, such as heart and lung diseases, asthma, ...
(Date:11/28/2014)... November 28, 2014 "Most of my life, ... to use crutches," said an inventor from Findlay, Ohio. "I ... way to support my foot, which inspired me to invent ... offer a convenient way to support an injured foot. The ... It eliminates the need for crutches. The design redistributes weight ...
Breaking Medicine News(10 mins):Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Don't Let Chronic Heartburn Spoil Your Thanksgiving Feast 2Health News:How Flu Vaccines Can Impact Families Is Discussed in New Article from Community Health Center of Snohomish County 2
... gastrointestinal bleeding accounts for approximately 20% of emergency ... has been used as a first-line treatment option ... be used as a safe diagnostic and treatment ... refractory to endoscopic treatment. The incidence of rebleeding ...
... , , , VIENNA, ... Industries Ltd. (Nasdaq: TEVA ), today announced results ... corticosteroids (ICSs) in a "real-life" asthmatic population. The study ... to effectively treat both large and small airway inflammation, to ...
... , WASHINGTON, Sept. 16 Antidepressant drug ... year, has been known to cause birth defects, but the ... a Philadelphia court has heard. , , ... the drug and urged scientists to conceal Paxil,s risks. The ...
... , , BRAINTREE, Mass. and ... HAE ) announced today that it has signed a ... a cooperative of community blood centers. The contract provides ... of innovative blood management software products, including Prelude and Interlude, ...
... finds supervised exercise has better results , WEDNESDAY, Sept. ... shockwave treatment for relieving chronic shoulder pain, according to ... to treat shoulder pain, even though a number of ... Norwegian researchers studied 104 men and women, aged 18 ...
... , , WASHINGTON, Sept. ... Orthotic and Prosthetic Association today announced that Senators Tom Harkin ... Miller, and Lincoln Diaz-Balart are recipients of their joint organizations, ... view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/aopa/40117/ ...
Cached Medicine News:Health News:Study Demonstrates That QVAR(R) is More Cost-Effective Than Other Inhaled Corticosteroid (ICS) Asthma Therapy Options 2Health News:Study Demonstrates That QVAR(R) is More Cost-Effective Than Other Inhaled Corticosteroid (ICS) Asthma Therapy Options 3Health News:Study Demonstrates That QVAR(R) is More Cost-Effective Than Other Inhaled Corticosteroid (ICS) Asthma Therapy Options 4Health News:Glaxo Official Memo Urged Scientists to Withhold Information About Paxil's Risks, Trial Hears; Pharmaceutical Industry Today Offers Complete News Coverage 2Health News:Haemonetics Signs Comprehensive Agreement with Blood Centers of America 2Health News:Shockwave Treatment May Not Be Best for Shoulder Pain 2Health News:Video: Members of Congress Receive Legislative Awards From National Amputee Organizations 2Health News:Video: Members of Congress Receive Legislative Awards From National Amputee Organizations 3
... of German Craftsmanship have ... instrumentation in the world. ... available to you! Only ... Meisterbrief certificate, which requires ...
... of German Craftsmanship have ... instrumentation in the world. ... available to you! Only ... Meisterbrief certificate, which requires ...
... German Craftsmanship have produced ... in the world. Ocutek ... to you! Only holders ... certificate, which requires and ...
... Ophthalmics offers the most comprehensive family ... Instruments for Cataract incision, Glaucoma filtration, ... coagulation is achieved with minimal tissue ... Straight eraser styles are available in ...
Medicine Products: